Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06995326
PHASE1

A Study of SGB-3383 in Healthy Subjects

Sponsor: Suzhou Sanegene Bio Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3383 in healthy subjects. The study will be designed as a single ascending dose (SAD) phase, utilizing a double-blind, placebo-controlled approach.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3383 in Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

37

Start Date

2025-06

Completion Date

2027-01

Last Updated

2025-06-03

Healthy Volunteers

Yes

Interventions

DRUG

SGB-3383

SGB-3383 for sc injection, single dose

DRUG

SGB-3383-Matching placebo

SC injection, single dose